LEN vs PFE · rev $34.19B vs P/E 20, rev $62.58B
LEN (LEN) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported PFE revenue for 2025-12-31 was $62.58B. Net income was $7.77B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
LEN currently screens at market cap $0. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the LEN and PFE stock pages for the full models.
Not investment advice.